Targacept to Present at 13th Annual BIO CEO & Investor Conference

WINSTON-SALEM, N.C.--(BUSINESS WIRE)-- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the 13th Annual BIO CEO & Investor Conference at The Waldorf=Astoria in New York City on Tuesday, February 15, 2011 at 10:00 a.m. Eastern Time.

Dr. deBethizy’s presentation will be webcast and accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Investor Calendar section of the Investor Relations page of Targacept’s website for at least two weeks following the event.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is being co-developed with AstraZeneca and is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad™ to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.

TARGACEPT
Building Health, Restoring IndependenceSM



CONTACT:

Targacept, Inc.
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
[email protected]
or
Linnden Communications
Michelle Linn, 508-362-3087
[email protected]

KEYWORDS:   United States  North America  New York  North Carolina

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Mental Health  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.